Goldman Sachs initiated coverage of Merus (MRUS) with a Buy rating and $73 price target The company’s most promising asset, petosemtamab, is a unique EGFR x LGR5 bispecific antibody being developed for head and neck squamous cell carcinoma with a total addressable market of 56,000 patients per year in the U.S. and Europe, the analyst tells investors in a research note. The firm sees “best-in-class potential” in a large market for petosemtamab. The next key Phase . 2 update in first-line could unlock higher value for the stock, contends Goldman.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRUS:
- Merus management to meet with Truist
- Merus N.V. Reports Q3 2024 Financial Results
- Merus reports Q3 EPS ($1.46), consensus (88c)
- Merus sees cash runway into 2028
- Merus NV (MRUS) Q3 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
